US2014179601A1PendingUtilityA1

Fgf-9 and its use relating to blood vessels

30
Individually held — no corporate assignee on recordPriority: May 2, 2008Filed: Nov 28, 2013Published: Jun 26, 2014
Est. expiryMay 2, 2028(~1.7 yrs left)· nominal 20-yr term from priority
Inventors:Geoffrey J. PickeringZengxuan NongMatthew Frontini
A61P 9/00A61K 48/00C07K 14/50A61K 38/1858A61P 9/10A61K 45/06A61K 38/1825A61P 35/00A61K 31/7088
30
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

There is provided a composition for controlling formation and/or stabilization of a blood vessel comprising a first isolated nucleic acid molecule that encodes a FGF-9 polypeptide and optionally one or more isolated nucleic acid molecule that encodes another angiogenic polypeptide. There is provided a composition for controlling formation and/or stabilization of a blood vessel comprising administering an effective amount of a composition comprising an isolated FGF-9 polypeptide and one or more other angiogenic polypeptides. The compositions provided herein may be useful for controlling angiogenesis and/or vasculogenesis.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A composition for promoting therapeutic angiogenisis in an animal comprising a first isolated nucleic acid molecule that encodes a FGF-9 polypeptide and a second isolated nucleic acid molecule that encodes an angiogenic polypeptide. 
     
     
         2 . The composition of  claim 1 , wherein the PGF-9 polypeptide comprises an amino acid sequence selected from the group consisting of: SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 and SEQ ID NO:4, or a variant thereof. 
     
     
         3 . The composition of  claim 2 , wherein the FGF 9 polypeptide comprises an amino acid sequence of SEQ ID NO:1 or a variant thereof that is at least 80% identical to the amino acid sequence of  FIG. 1  (SEQ ID NO:1). 
     
     
         4 . The composition of  claim 2 , wherein the angiogenic polypeptide is selected from the group consisting of FGF2, FGF4, FGF5, PDGF-β FGF-1, VEGF (and all its variant), P1GF, Hedgehog family member (Sonic, Indian and Desert), SDF-1 and IGF. 
     
     
         5 . The composition of  claim 2 , wherein the variant comprises an amino acid sequence having at least 80% identity with the amino acid sequence selected from the group consisting of: SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 and SEQ ID NO:4. 
     
     
         6 . The composition of  claim 1 , wherein the first isolated nucleic acid molecule comprises a nucleic acid sequence that hybridizes to the complement of the nucleic acid sequence that encodes an amino acid sequence selected from the group consisting of: SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 and SEQ ID NO:4, or a variant thereof. 
     
     
         7 . The composition of  claim 5 , wherein the hybridization occurs under stringent hybridization and wash conditions. 
     
     
         8 . The composition of any one of  claims 1  to  7 , wherein the first isolated nucleic acid molecule is comprised within a vector. 
     
     
         9 . The composition of any one of  claims 1  to  7 , wherein the first isolated nucleic acid molecule is comprised within a recombinant cell. 
     
     
         10 . The composition of  claim 9 , wherein the first isolated nucleic acid molecule is integrated into the chromosome of the recombinant cell. 
     
     
         11 . The composition of  claim 9 , wherein the first isolated nucleic acid molecule is extrachromosomal within the recombinant cell. 
     
     
         12 . The composition of any one of  claims 9  to  11 , wherein the recombinant cell is a stem cell. 
     
     
         13 . The composition of any one of  claims 1  to  12 , wherein the animal is a mammal. 
     
     
         14 . The composition of any one of  claims 1  to  12 , wherein the animal is a mammal selected from the group consisting of mouse, pig, dog, rat, and human. 
     
     
         15 . The composition of  claim 14 , wherein the mammal is a human. 
     
     
         16 . A composition for promoting therapeutic angiogenesis in an animal comprising an isolated FGF-9 polypeptide and one or more other angiogenic polypeptides. 
     
     
         17 . The composition of  claim 16 , wherein the FGF-9 polypeptide comprises an amino acid sequence selected from the group consisting of: SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 and SEQ ID NO:4, or a variant thereof. 
     
     
         18 . The composition of  claim 17 , wherein the FGF-9 polypeptide comprises an amino acid sequence of SEQ ID NO:1 or a variant thereof that is at least 80% identical to the amino acid sequence of SEQ ID NO:1. 
     
     
         19 . The composition of  claim 17 , wherein the other angiogenic polypeptide is selected from the group consisting of FGF2, FGF4, FGF5, and PDGF-β. 
     
     
         20 . The composition of  claim 17 , wherein the variant comprises an amino acid sequence having at least 80% identity with the amino acid sequence selected from the group consisting of: SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 and SEQ ID NO:4. 
     
     
         21 . The composition of  claim 17 , wherein the FGF-9 polypeptide comprises an amino acid sequence of SEQ ID NO:1. 
     
     
         22 . The composition of  claim 17 , wherein the other angiogenic polypeptide is FGF2. 
     
     
         23 . The composition of any one of  claims 17  to  22 , wherein the animal is a mammal. 
     
     
         24 . The composition of any one of  claims 17  to  22 , wherein the animal is a mammal selected from the group consisting of mouse, pig, dog, rat, and human. 
     
     
         25 . The composition of  claim 24 , wherein the mammal is human. 
     
     
         26 . A composition for promoting therapeutic angiogenesis in an animal comprising a recombinant cell producing an isolated FGF-9 polypeptide and another isolated angiogenic polypeptide. 
     
     
         27 . The composition of  claim 26 , wherein the FGF-9 polypeptide comprises an amino acid sequence selected from the group consisting of: SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 and SEQ ID NO:4, or a variant thereof. 
     
     
         28 . The composition of  claim 27 , wherein the FGF-9 polypeptide comprises an amino acid sequence of SEQ ID NO:1 or a variant thereof that is at least 80% identical to the amino acid sequence of SEQ ID NO:1. 
     
     
         29 . The composition of  claim 27 , wherein the other angiogenic polypeptide is selected from the group consisting of FGF2, FGF4, FGF5, and PDGF-β. 
     
     
         30 . The composition of  claim 27 , wherein the variant comprises an amino acid sequence having at least 80% identity with the amino acid sequence selected from the group consisting of: SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 and SEQ ID NO:4. 
     
     
         31 . The composition of  claim 27 , wherein the FGF-9 polypeptide comprises an amino acid sequence of SEQ ID NO:1. 
     
     
         32 . The composition of  claim 27 , wherein the other angiogenic polypeptide is FGF2. 
     
     
         33 . The composition of any one of  claims 27  to  32 , wherein the animal is a mammal. 
     
     
         34 . The composition of any one of  claims 27  to  32 , wherein the animal is a mammal selected from the group consisting of mouse, pig, dog, rat, and human. 
     
     
         35 . The composition of  claim 34 , wherein the mammal is a human. 
     
     
         36 . The composition of any one of  claims 27  to  35 , wherein the recombinant cell is a stem cell. 
     
     
         37 . The composition of any one of  claims 1  to  36 , further comprising a pharmaceutically acceptable carrier. 
     
     
         38 . The composition of any one of  claims 1  to  36 , further comprising a chelating agent. 
     
     
         39 . The composition of any one of  claims 1  to  36 , further comprising a preservative. 
     
     
         40 . A method of promoting formation of mature blood vessels in a subject comprising administering an effective amount of the composition of any one of  claims 1  to  39  to the subject. 
     
     
         41 . A method of treating ischemia in a subject comprising administering an effective amount of the composition of any one of  claims 1  to  39  to the subject. 
     
     
         42 . A use of the composition of any one of  claims 1  to  39  for preparation of a medicament. 
     
     
         43 . A use of the composition of any one of  claims 1  to  39  for preparation of a medicament for promoting formation of mature blood vessels in a subject. 
     
     
         44 . A use of the composition of any one of  claims 1  to  39  for preparation of a medicament for treating ischemia in a subject. 
     
     
         45 . A use of the composition of any one of  claims 1  to  39  for promoting formation of mature blood vessels in a subject. 
     
     
         46 . A use of the composition of any one of  claims 1  to  39  for treating ischemia in a subject. 
     
     
         47 . A kit comprising the composition of any one of  claims 1  to  39 , and instructions for administering the composition to a subject. 
     
     
         48 . A method of promoting formation of mature blood vessels in a subject comprising administering an effective amount of FGF-9 to the subject. 
     
     
         49 . A method of treating ischemia in a subject comprising administering an effective amount of FGF-9 to the subject. 
     
     
         50 . A use of FGF-9 for preparation of a medicament. 
     
     
         51 . A use of FGF-9 for preparation of a medicament for promoting for on of mature blood vessels in a subject. 
     
     
         52 . A use of FGF-9 for preparation of a medicament for treating ischemia in a subject. 
     
     
         53 . A use of FGF-9 for promoting formation of mature blood vessels in a subject. 
     
     
         54 . A use of FGF-9 for treating ischemia in a subject. 
     
     
         55 . A kit comprising FGF-9, and instructions for administering the composition to a subject. 
     
     
         56 . A kit comprising FGF-9 and a matrix material, and instructions for preparing an in vitro vasculogenesis assay. 
     
     
         57 . An in vitro vasculogenesis assay comprising a matrix material, FGF-9, endothelial cells, smooth muscle cells, and a matrix material for supporting growth and proliferation of all cells. 
     
     
         58 . Use of FGF-9 for stabilization of blood vessels in vitro or in vivo. 
     
     
         59 . The use of  claim 58 , wherein the blood vessels exhibit vascular leakage or are at risk of developing vascular leakage. 
     
     
         60 . The use of  claim 58 , wherein the blood vessels are within a tumour. 
     
     
         61 . The use of FGF-9 for treatment of cancer. 
     
     
         62 . A composition for improving the condition of a blood vessel in an animal, the composition comprising an isolated FGF-9 polypeptide and one or more other angiogenic polypeptides.

Join the waitlist — get patent alerts

Track US2014179601A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.